Arbelic (telavancin) / Cumberland, SciClone, Zymeworks - LARVOL DELTA

Zymeworks Completes Acquisition of Theravance Biopharma (Zymeworks Press Release) - "With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows."

M&A • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease

In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model. (PubMed, J Antimicrob Chemother) - "The telavancin 25 mg/mL formulation was better tolerated than the fortified vancomycin formulation tested in this model. These findings support further preclinical evaluation for MDR Gram-positive ocular infections."

Clinical • Journal • Preclinical • Infectious Disease • Ocular Infections • Ophthalmology

Zymeworks to Acquire Theravance Biopharma, Inc. (GlobeNewswire) - "This acquisition, when closed, provides Zymeworks with access to a 35% U.S. net profit share in YUPELRI, the only approved nebulized LAMA for the maintenance treatment of COPD...Settlements have been reached with all YUPELRI generic filers for an April 2039 licensed launch date for their versions of the product, or earlier depending on certain circumstances...Theravance Biopharma remains eligible to receive an additional $125 million in commercial milestone payments from Viatri...Theravance Biopharma is expected to receive $100 million in commercial milestone payments from Royalty Pharma in Q1 2027 related to global net sales of TRELEGY ELLIPTA by GSK....Theravance Biopharma is eligible to receive up to ~20% royalty on net sales of VIBATIV from Cumberland."

Financing • M&A • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials. (PubMed, Infection) - "Despite the growth of newer anti-MRSA agents, vancomycin remains clinically comparable for MRSA-confirmed SSTI, with apparent microbiological advantages of alternatives tempered by potential publication bias. Varying safety and pharmacological profiles of these agents emphasize the importance of individualized treatment selection."

Journal • Retrospective data • Hematological Disorders • Infectious Disease

MULTIVALVULAR MRSA ENDOCARDITIS IN A PATIENT WITH UNREPAIRED CONGENITAL VENTRICULAR SEPTAL DEFECT COMPLICATED BY SYSTEMIC SEPTIC EMBOLI AND MULTIPLE ANTIMICROBIAL RESISTANCE (ACC 2026) - "Decision-Making: Bacteremia persisted despite antibiotic treatment suggesting vancomycin resistance, prompting a switch to telavancin & gentamicin with adequate bacteremic clearance. IE should be considered in adults with unrepaired low-risk CHD presenting with prolonged fever, surgical intervention remains effective in cases of massive vegetations."

Clinical • Cardiovascular • Heart Failure • Infectious Disease • Pulmonary Disease • CRP

N-(ω-Guanidinoalkyl)amides of Eremomycin: New Type of Glycopeptides with High Potency against Planktonic Forms and Biofilms of Resistant Bacteria. (PubMed, ACS Infect Dis) - "N-(2-Guanidinoethyl)amide of eremomycin (12a) exhibited superior in vitro activity against both vancomycin-sensitive and -resistant strains, including VRE and MRSE, and showed enhanced potency compared to vancomycin, telavancin, and previously reported eremomycin analogs without hemolytic or cytotoxic effects. In vivo evaluation in a murine sepsis model demonstrated that compound 12a had an ED50 value 14 times lower than that of vancomycin, highlighting its strong therapeutic potential. These findings suggest that guanidine-functionalized eremomycin amides represent a promising new class of glycopeptide antibiotics capable of addressing both resistance and biofilm-related challenges."

Journal • Infectious Disease • Septic Shock

Proportion and antibiogram of methicillin-resistant Staphylococcus aureus (MRSA) in Africa: a systematic review and meta-analysis. (PubMed, Antimicrob Resist Infect Control) - "The proportion of MRSA in Africa remains high at 42.2%, with marked regional disparities. Although resistance rates for linezolid and vancomycin are relatively low, they surpass global averages, raising concerns about emerging resistance. Alarmingly high resistance rates to several other antibiotics further underscore the urgent need for targeted interventions and continuous surveillance."

Journal • Retrospective data • Infectious Disease

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage (clinicaltrials.gov) - P4 | N=20 | Recruiting | Sponsor: Aaron Cook | Trial completion date: Jan 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis. (PubMed, BMC Infect Dis) - "Our findings indicate that omadacycline is a promising treatment option for ABSSSI, demonstrating efficacy that is comparable to or potentially superior to many other anti-MRSA agents, along with a favorable safety profile. However, these results should be interpreted with caution due to the study's inherent limitations."

Clinical • Journal • Retrospective data • Review • Infectious Disease

In vitro persistence of clinical methicillin-resistant Staphylococcus aureus isolates from bone and joint infections after exposure to daptomycin, telavancin, and vancomycin. (PubMed, Microbiol Spectr) - "Although daptomycin, telavancin, and vancomycin are widely used for the treatment of bone and joint infections, their persister potential has not been assessed under the same experimental conditions. The present study sought to assess the in vitro persister potential of daptomycin, telavancin, and vancomycin against clinical MRSA from bone and joint infections."

Journal • Preclinical • Infectious Disease

In Vitro Persistence of Clinical Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Bone and Joint infections after Exposure to Daptomycin (DAP), Telavancin (TLV), and Vancomycin (VAN) (IDWeek 2025) - No abstract available

Preclinical • Infectious Disease

Critical genomic insights into vancomycin-resistant Enterococcus faecium in Lebanon. (PubMed, Microbiol Spectr) - "Our VRE isolates carried multiple acquired AMR genes and chromosomal mutations, exhibiting resistance to vancomycin, telavancin, ampicillin, erythromycin, norfloxacin, levofloxacin, and nitrofurantoin...Resistance to novel antimicrobials, such as telavancin, dalbavancin, and eravacycline, is alarming and necessitates immediate action to preserve these critical last-resort interventions. Notably, the identification of clonal spread and a novel sequence type (ST2711) within Lebanese hospitals, alongside resistance to last-resort antimicrobials, highlights the dynamic evolution of VRE and the urgent need to strengthen antimicrobial stewardship programs in Lebanon and beyond. Addressing this challenge requires integrated One Health strategies."

Journal • Infectious Disease

Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections. (PubMed, Antimicrob Agents Chemother) - "The model for ELF did not reveal any appreciable biases and determined the average free-drug ELF penetration ratio to be 73.0%. In summary, the population PK model characterized the time course of telavancin in both plasma and ELF robustly, captured the impact of clinically meaningful patient covariate effects, including removal of drug due to hemodialysis, and provided reliable individual post hoc estimates of exposure in subjects enrolled in the clinical studies."

Journal • PK/PD data • Infectious Disease • Pneumonia • Respiratory Diseases

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. (PubMed, Cureus) - "Telavancin is a fairly novel antibiotic derived from vancomycin developed to combat the constant evolutionary war against bacteria. It has achieved high clinical success in its role in treating Gram-positive organisms, although like in the case of any other antibiotics, failure can arise. The purpose of this article is to describe a case in which telavancin clinically failed in treating persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a patient while describing the cause that led to telavancin failure."

Journal • Infectious Disease

History of the Creation of a New Generation of Antibiotics of the Group of Polycyclic Glycopeptides (PubMed, Mol Biol (Mosk)) - "Over the past two decades, a series of hydrophobic glycopeptide analogues active against resistant strains of Gram-positive bacteria have been developed, three of which - oritavancin, telavancin, and dalbavancin - were approved by the US Food and Drug Administration (FDA) in 2013-2014 for the treatment of infections caused by sensitive and resistant strains of staphylococci and enterococci. The possibility of using semi-synthetic glycopeptide analogues in the fight against viral infections caused by enveloped viruses is also considered. This review outlines the main ways of chemical design in creating a new generation of glycopeptide antibiotics that overcome resistance to Gram-positive pathogens and the mechanisms of their action."

Journal • Review • Infectious Disease

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA (PRNewswire) - "Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc...and SciClone Pharmaceuticals (Holdings) Limited ('SciClone Pharmaceuticals' or 'SciClone') today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product to patients in that country."

China approval • Infectious Disease • Pneumonia

Telavancin Use in Hospitalized Patients with Diminished Renal Clearance (ASHP 2024) - No abstract available

Clinical

Embryonic exposure to glycopeptides induces acute toxicity and developmental neurotoxicity in zebrafish (Danio rerio). (PubMed, J Hazard Mater) - "Our findings indicate that oritavancin (ORI) and telavancin (TEL) exhibit greater acute toxicity compared to vancomycin (VAN). The disruption of neurodevelopmental pathways suggests mechanisms through which these compounds influence development. These findings underscore the critical role of glycopeptide structure in toxicity and emphasize the need for further research to delineate specific affected molecular pathways, which could guide future studies and treatments for neurodevelopmental disorders."

Journal • CNS Disorders • Developmental Disorders • Infectious Disease • Psychiatry

Telavancin and Cardiac Surgery: Balancing Antimicrobial Efficacy With Coagulation Challenges. (PubMed, J Cardiothorac Vasc Anesth) - No abstract available

Journal • Surgery • Cardiovascular

Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis. (PubMed, Antibiotics (Basel)) - "This systematic review and NMA provide a new comparison framework for the clinical treatment of MRSA infection. The NMA suggests that linezolid may be the antibiotic of choice for the treatment of MRSA infections, with the ability to improve clinical and microbiological success rates despite its disadvantage in terms of adverse effects. At the same time, the combination of minocycline and rifampicin may be the most effective drug to treat MRSA-induced cSSSIs, tedizolid may be the best drug to treat MRSA-induced cSSTIs, and the combination of vancomycin and rifampicin may be the most effective treatment for MRSA-induced pneumonia. More high-quality studies are still needed in the future to further identify alternatives to vancomycin."

Journal • Retrospective data • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Telavancin Outcomes in Infections Treated with Outpatient Parenteral Antibiotic Therapy (OPAT) (IDWeek 2024) - No abstract available

Clinical • Infectious Disease

Telavancin for Refractory MRSA Bacteremia: A 10-Year Retrospective Review (IDWeek 2024) - No abstract available

Retrospective data • Review • Infectious Disease

Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity. (PubMed, Sci Transl Med) - "In recent years, semisynthetic vancomycin derivatives have been developed to overcome this problem as exemplified by the clinically used telavancin, which exhibits increased antibacterial potency but has also raised toxicity concerns. Moreover, the minimal to mild kidney effects at supratherapeutic doses of EVG7 indicate an improved therapeutic safety profile compared with vancomycin. These findings position guanidino lipoglycopeptides as candidates for further development as antibacterial agents for the treatment of clinically relevant multidrug-resistant Gram-positive infections."

Journal • Preclinical • Infectious Disease • Septic Shock

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years) (clinicaltrials.gov) - P1 | N=22 | Terminated | Sponsor: Cumberland Pharmaceuticals | Phase classification: P4 ➔ P1

Phase classification • Infectious Disease • Pediatrics

Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model. (PubMed, Antimicrob Agents Chemother) - "Further, telavancin conveyed 100% survival in this model and cleared B. anthracis from the bloodstream and organ tissues more effectively than a humanized dose of levofloxacin. Collectively, the low MICs against all strains tested and rapid bactericidal in vivo activity demonstrate that telavancin has the potential to be an effective alternative for the treatment or prophylaxis of anthrax infection."

Journal • Preclinical • Infectious Disease